As a specific GLUT1 inhibitor, WZB117 not only resensitizes resistant breast cancer cells to ADR (Chen et al. 2017), but also effectively overcomes resistance in gastrointestinal stromal tumor cells when combined with imatinib (Shima et al. 2022). Here, SLC2A1 is linked to breast carcinoma.